SEC Comment Letter 0000000000-24-012305 to Silexion Therapeutics Corp (SLXN)
Silexion Therapeutics Corp
Date: Nov. 5, 2024 · CIK: 0002022416 · Accession: 0000000000-24-012305
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282932
Letter
November 5, 2024 Ilan Hadar Chief Executive Officer Silexion Therapeutics Corp 12 Abba Hillel Road Ramat Gan, Israel 5250606 Re:Silexion Therapeutics Corp Registration Statement on Form S-1 Filed October 31, 2024 File No. 333-282932 Dear Ilan Hadar: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Jonathan M. Nathan, Adv.
Show Raw Text
November 5, 2024
Ilan Hadar
Chief Executive Officer
Silexion Therapeutics Corp
12 Abba Hillel Road
Ramat Gan, Israel 5250606
Re:Silexion Therapeutics Corp
Registration Statement on Form S-1
Filed October 31, 2024
File No. 333-282932
Dear Ilan Hadar:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Jonathan M. Nathan, Adv.